COMMUNIQUÉS West-GlobeNewswire

Ibogaine By David Dardashti Investigates Impact of Quantum Physics on April 8 Solar Eclipse
05/04/2024
A Unique Opportunity to Experience the Unprecedented Potential of Ibogaine Treatment Based on Quantum Electrodynamics MIAMI, April 04, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti has uncovered a unique [...]
Sirona Biochem Announces Close of Private Placement
05/04/2024
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Vancouver, British Columbia – April 4, 2024 – Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (“ Sirona ”) has closed its private placement (Private [...]
Contineum Therapeutics Announces Pricing of Initial Public Offering
05/04/2024
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target [...]
Digicann Ventures Grants Restricted Share Units
05/04/2024
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Digicann Ventures Ltd. (“Digicann” or the “Company”) (CSE: DCNN) (OTCPK: AGFAD), a company focused on opportunities within and outside of the cannabis [...]
CORRECTION : Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
05/04/2024
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 avr. 2024 (GLOBE NEWSWIRE) -- Ce document corrige et remplace le communiqué de presse diffusé le 4 avril à 16:30 heure de l'Est. Place [...]
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
05/04/2024
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat [...]
MESA LABS DECLARES QUARTERLY DIVIDEND
05/04/2024
LAKEWOOD, Colo., April 04, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $ [...]
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024
04/04/2024
Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2024
04/04/2024
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2024 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/04/2024
CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( [...]
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
04/04/2024
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
04/04/2024
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 avr. 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting
04/04/2024
PREDATOR protein engineering technology allows for the expansion of INDUKINE™ molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory bowel disease WATERTOWN [...]
Monthly information on share capital and company voting rights
04/04/2024
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, April 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
04/04/2024
Posters to be presented highlighting research investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Travere [...]
Clover Health Provides Notice Associated with Previously Disclosed Settlement of Shareholder Derivative Actions
04/04/2024
FRANKLIN, Tenn., April 04, 2024 (GLOBE NEWSWIRE) -- As previously disclosed, most recently in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its Quarterly Report on Form 10-Q for the [...]
Kno2 Launches New MuleSoft Integration
04/04/2024
Kno2's new MuleSoft Certified Connector for Salesforce helps healthcare providers create digital experiences, faster BOISE, Idaho, April 04, 2024 (GLOBE NEWSWIRE) -- Kno2, today announced a new MuleSoft Certified [...]
GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
04/04/2024
Cash and cash equivalents totaled €77.8 million as of December 31, 2023 Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 million Topline interim data for Phase 2 UNVEIL- [...]
GENFIT : Résultats financiers annuels 2023 et point sur les activités de la Société
04/04/2024
Trésorerie et équivalents de trésorerie s’élevant à 77,8 millions d’euros au 31 décembre 2023 Chiffre d’affaires : 28,6 millions d’euros au 31 décembre 2023, dont un paiement d’étape de 13,3 millions d’euros Premières [...]

Pages